A 2011 study established that kisspeptin-10 can acutely stimulate luteinizing-hormone secretion in healthy men. Its detailed pulse data are valuable physiology, but the very small cohorts do not establish a treatment outcome.
Evidence at a glance
- Bolus experiments included six healthy men; prolonged infusion analyses used groups of four.
- After one studied bolus condition, mean LH rose from 4.1 ± 0.4 to 12.4 ± 1.7 IU/L at 30 minutes.
- At a lower infusion condition, LH pulse frequency rose from 0.7 ± 0.1 to 1.0 ± 0.2 pulses/hour.
Study record
The dose-response experiment found a rapid LH rise with maximal stimulation at one tested condition; a higher tested condition produced a smaller response. That non-linear result is a reminder that more exposure cannot be assumed to create more endocrine response.
Results in context
During the lower-rate infusion, secretory burst mass rose from 3.9 ± 0.4 to 12.8 ± 2.6 IU/L. A higher-rate experiment increased mean LH and testosterone, but the sample was only four participants and the intense secretion obscured pulse detection.
A later experiment in men with type 2 diabetes and mild biochemical hypogonadism also observed an LH response. It addressed pathway responsiveness, not pregnancy, live birth, chronic replacement or safety.
What the evidence cannot establish
The cohorts were too small to estimate uncommon adverse events or population variability.
Hormone changes are surrogate physiological endpoints, not direct evidence of fertility or clinical benefit.
The experimental material was not analytically linked to a catalog lot.
Sources & editorial method
The editorial workflow began with linked PubMed primary papers, systematic reviews, PubChem identity records and FDA/DailyMed regulatory records. Population or model, denominators, endpoints, numerical results, null findings, limitations and conflicts were extracted before drafting. AI-assisted drafting and original image generation were used; the final facts and evidence boundaries were checked against the linked records on 2026-09-02. This is not independent peer review.
4 linked records are listed in the references below. Read the editorial and AI-assistance policy.
How to interpret this article
Source-checked on 2026-09-02. Null results, study size, model/population limits and relevant conflicts are retained. This is not medical advice, a customer case or validation of a catalog lot.
Research-use boundary: Catalog materials discussed on this website are for laboratory research, development and manufacturing use only, not for human or veterinary use. This content is not medical advice and does not provide administration instructions.
Primary records and authoritative sources
- Kisspeptin-10 is a potent stimulator of LH release in menHuman study. 2011. PMID 21632807.
- Kisspeptin-10 response in men with type 2 diabetesSmall human pathway-response study; PMID 23153270.
- PubChem Kisspeptin-10 recordSequence, formula and mass; CID 25240297.
- PubChem Kisspeptin-54 recordLonger peptide identity; CID 71306396.
Continue with structured records
Move from this editorial analysis to the product identity, filtered evidence and controlled terminology behind it.
